CorrlensCorrlens
Correlate

Correlation Analysis

Biogen Inc. Common Stock vs Eli Lilly & Co.

BIIB vs LLY

-0.667

Strong inverse

When one moves up, the other tends to move down.

BIIB logo

Biogen Inc. Common Stock

BIIB

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Market cap 25.3B · 7,500 employees

LLY logo

Eli Lilly & Co.

LLY

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Market cap 828.2B · 50,000 employees

Apr 9, 2021 — Apr 7, 2026Daily1,253 data pointsStockStockHealthcare

Time Series

Relative Performance

Green: BIIBGray: LLY36 of 1,253 points (sampled)

Who Moves First

LLY leads BIIB by 6 days

LLY tends to move before BIIB.

After testing 13 timing shifts, the strongest relationship was -0.673 (they moved in opposite directions).

Do They Crash Together?

Correlation by Market Regime

How these series behave when markets are rising, falling, or diverging. A correlation that holds in drawdowns is very different from one that only works in rallies.

Both Rising

-0.002

9 periods · Return correlation when both series rose

Both Falling

+0.430

5 periods · Return correlation when both series fell

Diverging

-0.440

21 periods · Return correlation when series moved apart

R-Squared

44.4%

Share of variance in one series explained by the other.

Trend Agreement

60.2%

How often both series moved in the same direction period-to-period.

Overlap Quality

1,253

Deep shared window — 1,253 usable pairs.

Significance

p < 0.001

95% CI: [-0.696, -0.635]

Scatter

XY Regression

102.6150200250300342.91142004006008001,0001,142Biogen Inc. Common StockEli Lilly & Co.Data pointsFit (r = -0.667)

Pipeline

Data quality details

Pipeline Summary

1,253 paired data points survived the daily window.

Raw input

1,253

1,254

Normalized

1,253

1,254

Prepared

1,253

1,254

Aligned

1,253

1,253

Invalid removed

0

A: 0 / B: 0

Duplicates removed

0

A: 0 / B: 0

Alignment drops

1

A: 0 / B: 1

Series A

BIIB logo

Biogen Inc. Common Stock

BIIB

Market cap 25.3B · 7,500 employees

Stock · 1,253 raw → 1,253 prepared

Series B

LLY logo

Eli Lilly & Co.

LLY

Market cap 828.2B · 50,000 employees

Stock · 1,254 raw → 1,254 prepared

Sign agreement

100.0%

How often both values share the same sign.

Zero crossings

5

Estimated crossover points between normalized spreads.

Slope

-3.0359

Linear regression slope.

Intercept

1247.4878

Linear regression intercept.

Related Extremes

Highest and Lowest Correlated

Saved 6 hours ago · ID: stock-biib-vs-stock-lly-daily